文献速递重症综合管理与镇静镇痛呼吸衰竭与机械通气

数字PCR在重症医学感染诊断与管理中的应用

Digital PCR applications for the diagnosis and management of infection in critical care medicine.
PubMed 文献 · Crit Care · 2022-03-21
一句话结论综述32篇文献显示,数字PCR可能有助于改善重症医学中感染的检测与临床管理,但证据尚待进一步积累。

该综述汇总了32篇涉及危重症患者的文献,评估数字PCR(dPCR)在重症医学感染管理中的应用。dPCR较实时PCR受PCR抑制剂影响小、灵敏度更高、重复性好且无需标准曲线即可绝对定量。23篇文献聚焦微生物基因扩增,包括细菌、真菌、病毒鉴定、微生物负荷定量及微生物生态;9篇文献分析宿主对感染的反应,用于脓毒症严重度分层、诊断改进、sCAP和VAP检测及COVID-19进展预测。综述认为dPCR有潜力成为改善重症感染检测与临床管理的工具。

要点

  • 综述纳入32篇涉及危重症患者的文献,其中23篇聚焦微生物基因扩增,9篇分析宿主对感染的反应。
  • dPCR较实时PCR受PCR抑制剂影响小,灵敏度更高,重复性好,无需标准曲线即可绝对定量。
  • 12篇文献用dPCR定量微生物负荷以评估严重度、预后和治疗指导,2篇用于脓毒症严重度分层。
  • 4篇文献聚焦血液或血浆中细菌鉴定,1篇用dPCR检测血液中真菌,3篇用于病毒鉴定。
  • 4篇文献用dPCR改进脓毒症诊断,各1篇用于检测sCAP、VAP和预测COVID-19进展。

适用人群与场景

  • 危重症患者,包括社区获得性或医院获得性感染、脓毒症、重症社区获得性肺炎(sCAP)、呼吸机相关性肺炎(VAP)和血流感染(BSIs)患者。
  • ICU患者中脓毒症发生率高达30%,VAP影响10-25%的机械通气患者,BSIs影响约10%的患者。

研究设计与关键结果

  • 综述纳入32篇涉及危重症患者的文献:23篇聚焦微生物基因扩增,其中4篇用于血液或血浆中细菌鉴定、1篇用于血液中真菌鉴定、1篇用于其他临床样本中细菌和真菌鉴定、3篇用于病毒鉴定、12篇通过dPCR定量微生物负荷以评估严重度、预后和治疗指导、2篇用于确定ICU患者微生物生态。
  • 其余9篇用dPCR分析宿主对感染的反应:2篇用于脓毒症严重度分层,4篇聚焦改进脓毒症诊断,1篇用于检测sCAP,1篇用于检测VAP,1篇旨在预测COVID-19进展。

证据类型、等级与局限

  • 证据类型:综述,纳入32篇涉及危重症患者的文献。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 综述认为dPCR有潜力成为有助于改善重症医学感染检测与临床管理的工具。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Infection (either community acquired or nosocomial) is a major cause of morbidity and mortality in critical care medicine. Sepsis is present in up to 30% of all ICU patients. A large fraction of sepsis cases is driven by severe community acquired pneumonia (sCAP), which incidence has dramatically increased during COVID-19 pandemics. A frequent complication of ICU patients is ventilator associated pneumonia (VAP), which affects 10-25% of all ventilated patients, and bloodstream infections (BSIs), affecting about 10% of patients. Management of these severe infections poses several challenges, including early diagnosis, severity stratification, prognosis assessment or treatment guidance. Digital PCR (dPCR) is a next-generation PCR method that offers a number of technical advantages to face these challenges: it is less affected than real time PCR by the presence of PCR inhibitors leading to higher sensitivity. In addition, dPCR offers high reproducibility, and provides absolute quantification without the need for a standard curve. In this article we reviewed the existing evidence on the applications of dPCR to the management of infection in critical care medicine. We included thirty-two articles involving critically ill patients. Twenty-three articles focused on the amplification of microbial genes: (1) four articles approached bacterial identification in blood or plasma; (2) one article used dPCR for fungal identification in blood; (3) another article focused on bacterial and fungal identification in other clinical samples; (4) three articles used dPCR for viral identification; (5) twelve articles quantified microbial burden by dPCR to assess severity, prognosis and treatment guidance; (6) two articles used dPCR to determine microbial ecology in ICU patients. The remaining nine articles used dPCR to profile host responses to infection, two of them for severity stratification in sepsis, four focused to improve diagnosis of this disease, one for detecting sCAP, one for detecting VAP, and finally one aimed to predict progression of COVID-19. This review evidences the potential of dPCR as a useful tool that could contribute to improve the detection and clinical management of infection in critical care medicine.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Merino I, de la Fuente A, Domínguez-Gil M, et al. Digital PCR applications for the diagnosis and management of infection in critical care medicine. Crit Care. 2022. PMID: 35313934. doi:10.1186/s13054-022-03948-8

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。